Sublingual Semaglutide (Aspire Biopharm)

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameSublingual Semaglutide (Aspire Biopharm)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAspire Biopharma Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesAspire Biopharma Holdings Inc
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A